Literature DB >> 36098485

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.

Natsuko Macabuag1, William Esmieu1, Perla Breccia1, Rebecca Jarvis1, Wesley Blackaby1, Ovadia Lazari1, Liudvikas Urbonas1, Maria Eznarriaga1, Rachel Williams1, Annelieke Strijbosch2, Rhea Van de Bospoort2, Kim Matthews1, Cole Clissold1, Tammy Ladduwahetty1, Huw Vater1, Patrick Heaphy3, Douglas G Stafford3, Hong-Jun Wang3, John E Mangette3, George McAllister4, Vahri Beaumont4, Thomas F Vogt4, Hilary A Wilkinson4, Elizabeth M Doherty4, Celia Dominguez4.   

Abstract

Huntington's disease (HD) is a lethal autosomal dominant neurodegenerative disorder resulting from a CAG repeat expansion in the huntingtin (HTT) gene. The product of translation of this gene is a highly aggregation-prone protein containing a polyglutamine tract >35 repeats (mHTT) that has been shown to colocalize with histone deacetylase 4 (HDAC4) in cytoplasmic inclusions in HD mouse models. Genetic reduction of HDAC4 in an HD mouse model resulted in delayed aggregation of mHTT, along with amelioration of neurological phenotypes and extended lifespan. To further investigate the role of HDAC4 in cellular models of HD, we have developed bifunctional degraders of the protein and report the first potent and selective degraders of HDAC4 that show an effect in multiple cell lines, including HD mouse model-derived cortical neurons. These degraders act via the ubiquitin-proteasomal pathway and selectively degrade HDAC4 over other class IIa HDAC isoforms (HDAC5, HDAC7, and HDAC9).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36098485      PMCID: PMC9512014          DOI: 10.1021/acs.jmedchem.2c01149

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  43 in total

1.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.

Authors:  Kanak Raina; Jing Lu; Yimin Qian; Martha Altieri; Deborah Gordon; Ann Marie K Rossi; Jing Wang; Xin Chen; Hanqing Dong; Kam Siu; James D Winkler; Andrew P Crew; Craig M Crews; Kevin G Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

Review 2.  Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.

Authors:  Scott D Edmondson; Bin Yang; Charlene Fallan
Journal:  Bioorg Med Chem Lett       Date:  2019-04-20       Impact factor: 2.823

Review 3.  Practical approaches to evaluating and optimizing brain exposure in early drug discovery.

Authors:  Burgess B Freeman; Lei Yang; Zoran Rankovic
Journal:  Eur J Med Chem       Date:  2019-08-23       Impact factor: 6.514

4.  Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.

Authors:  A Lahm; C Paolini; M Pallaoro; M C Nardi; P Jones; P Neddermann; S Sambucini; M J Bottomley; P Lo Surdo; A Carfí; U Koch; R De Francesco; C Steinkühler; P Gallinari
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

Review 5.  Designing HDAC-PROTACs: lessons learned so far.

Authors:  Fabian Fischer; Leandro A Alves Avelar; Laoise Murray; Thomas Kurz
Journal:  Future Med Chem       Date:  2021-12-24       Impact factor: 3.808

6.  Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters.

Authors:  Irina V Lebedeva; Praveen Pande; Wayne F Patton
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

7.  Solution Conformations Shed Light on PROTAC Cell Permeability.

Authors:  Yoseph Atilaw; Vasanthanathan Poongavanam; Caroline Svensson Nilsson; Duy Nguyen; Anja Giese; Daniel Meibom; Mate Erdelyi; Jan Kihlberg
Journal:  ACS Med Chem Lett       Date:  2020-12-25       Impact factor: 4.345

8.  Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.

Authors:  Joshua P Smalley; India M Baker; Wiktoria A Pytel; Li-Ying Lin; Karen J Bowman; John W R Schwabe; Shaun M Cowley; James T Hodgkinson
Journal:  J Med Chem       Date:  2022-03-16       Impact factor: 8.039

9.  HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.

Authors:  Michal Mielcarek; Christian Landles; Andreas Weiss; Amyaouch Bradaia; Tamara Seredenina; Linda Inuabasi; Georgina F Osborne; Kristian Wadel; Chrystelle Touller; Rachel Butler; Janette Robertson; Sophie A Franklin; Donna L Smith; Larry Park; Paul A Marks; Erich E Wanker; Eric N Olson; Ruth Luthi-Carter; Herman van der Putten; Vahri Beaumont; Gillian P Bates
Journal:  PLoS Biol       Date:  2013-11-26       Impact factor: 8.029

10.  Developing degraders: principles and perspectives on design and chemical space.

Authors:  Hannah J Maple; Nat Clayden; Anne Baron; Callum Stacey; Robert Felix
Journal:  Medchemcomm       Date:  2019-08-12       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.